AURAVAX THERAPEUTICS, INC. — Federal Contracts, Awards & Government Contractor Profile

About AURAVAX THERAPEUTICS, INC.

AuraVax Therapeutics, Inc. is developing the NanoSTING platform, a broad-acting intranasal host-directed-therapeutic that activates the STING pathway to boost innate immunity for the prevention and treatment of respiratory infections. The company is focused on both therapeutic and vaccine adjuvant applications.

Development of host-directed-therapeutics (HDTs) for respiratory infectionsCreation of mucosal adjuvants for intranasal vaccinesActivation of the STING pathway to enhance innate immunityAdministration before or after pathogen exposure to prevent or reduce infection severitySupply chain independence from cryopreservation

Recent Federal Awards

Award	Agency	Amount	Date
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOS	Department of Health and Human Services	$750K

Is this your company?

Claim AURAVAX THERAPEUTICS, INC. to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.

Claim AURAVAX THERAPEUTICS, INC. & see your matches

Free to claim. Takes about a minute.

Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.